In patients with advanced lung or breast cancer and grade 2 to 4 neurotoxicity, adding thymosin alpha‑1 to the next chemotherapy cycle reduced neurotoxicity to below grade 2 in 10 patients (45.4%).
In plain wordsIn people with advanced cancer and nerve damage from chemotherapy, adding thymosin alpha‑1 lowered nerve damage to a mild grade in 10 patients.
- Peptide
- Thymosin alpha-1
- Outcome
- DecreaseChemotherapy-induced neurotoxicity grade
- Study
n = 22
- Comparator
- Previous chemotherapy cycle without thymosin alpha 1
- Outcome group
- Neuroprotection · Nervous system and cognition
- Studied dose
- 1.6 mg/d for 4 days before chemotherapy, then 1.6 mg twice weekly for 1-3 weeks after chemotherapy beganAs given in this study (human).
Measurements
- Patients with neurotoxicity reduced to below grade 2
- 10 patients
- 45.4%
Source sentences
In 10 patients (45.4%), neurotoxicities reduced from grade 2-4 before chemotherapy to less than grade 2 after chemotherapy.
2 context sentences(design, population, supporting numbers)
They all experienced grade 2 to 4 of neurotoxicities according to common toxicity criteria of National Cancer Institute after chemotherapy.
The same chemotherapy regimens were combined with thymosin alpha1 (1.6 mg/d for 4 days before chemotherapy, and 1.6 mg twice weekly for 1-3 weeks after chemotherapy began) in the next cycle.